Publications



Cardiology

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. SW Worm, C Sabin, R Weber, P Reiss, W El-Sadr, F Dabis, S De Wit, M Law, AD Monforte, N Friis-Møller, O Kirk, E Fontas, I Weller, A Phillips, J Lundgren. J Infect Dis. 2010 Feb 1;201(3):318-30

High Prevalence of the Metabolic Syndrome in HV-infected patients: Impact of Different Definitions of the Metabolic Syndrome. SW Worm, N Friis-Møller, M Bruyand, A D'Arminio Monforte, M Rickenbach, P Reiss, W El-Sadr, A Phillips, J Lundgren, C Sabin; D:A:D study group
AIDS. 2010 Jan 28;24(3):427-35.

Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D study). SW Worm, CA Sabin, P Reiss, W El-Sadr, A Monforte, C Pradier, R Thiebaut, M Law, M Rickenbach, S De Wit, JD Lundgren, N Friis-Møller.Diabetes Care. 2009 Mar;32(3):474-80.

What a cardiologist needs to know about patients with human immunodeficiency virus infection. PY Hsue, DD Waters.
Circulation. 2005 Dec 20;112(25):3947-57.


Diabetes
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. SW Worm, C Sabin, R Weber, P Reiss, W El-Sadr, F Dabis, S De Wit, M Law, AD Monforte, N Friis-Møller, O Kirk, E Fontas, I Weller, A Phillips, J Lundgren.
J Infect Dis. 2010 Feb 1;201(3):318-30

High Prevalence of the Metabolic Syndrome in HV-infected patients: Impact of Different Definitions of the Metabolic Syndrome. SW Worm, N Friis-Møller, M Bruyand, A D'Arminio Monforte, M Rickenbach, P Reiss, W El-Sadr, A Phillips, J Lundgren, C Sabin; D:A:D study group
AIDS. 2010 Jan 28;24(3):427-35.

Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D study). SW Worm, CA Sabin, P Reiss, W El-Sadr, A Monforte, C Pradier, R Thiebaut, M Law, M Rickenbach, S De Wit, JD Lundgren, N Friis-Møller.
Diabetes Care. 2009 Mar;32(3):474-80.


Haematology
Current haemoglobin levels are more predictive of disease progression than haemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV-1 infection. JD Kowalska, A Mocroft, A Blaxhult, R Colebunders, J van Lunzen, D Podlekareva, A-BE Hansen, L Machala, I Yust and T Benfield for the EuroSIDA Study Group.
AIDS Res Hum Ret. 2007; 23 (10): 1183-1188

Zidovudine in asymptomatic human immunodeciency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimetre. PA Volberding, SW Lagakos, MA Koch, et al.
N Engl J Med 1990; 322:941-9

Mean cell volume (MCV) changes in HIV-positive patients taking nucleoside reverse transcriptase inhibitors (NRTIs): a surrogate marker for adherence. RH Steele, GL Keogh, J Quin, SL Fernando, V Stojkova.
Int J STD AIDS 2002;13:748-754

Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection. F Romanelli, K Empey, C Pomeroy.
AIDS Patient Care STDs 2002;16:405-411


Hepatology
HIV-related liver disease: ARV drugs, coinfection, and other risk factors. Puoti et al.
J Int Assoc Physicians AIDS Care 2009; 8:30-42.

Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. Labarga et al.
J Infect Dis 2007; 196:670-6.

Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. Mocroft A et al.
AIDS Res Hum Retroviruses 2005; 21:743-52.

Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study. Dominguez et al.
J Antimicrob Chemother 2010.